ST天圣索赔已递交立案，维权通道持续开启

Core Viewpoint - The company Tian Sheng Pharmaceutical has been found guilty of financial misconduct, including inflating profits and failing to disclose related party transactions, leading to a formal administrative penalty from regulators [1][2]. Group 1: Regulatory Actions - On November 8, Tian Sheng Pharmaceutical announced receipt of an administrative penalty decision from regulators, confirming violations in their 2017 and 2018 annual reports [1][2]. - The company is currently facing legal actions, with a case submitted to the court by a law firm representing affected investors [1]. Group 2: Violations Identified - The company inflated profits by approximately 120 million yuan over the years 2017 and 2018 through various means, including misappropriating funds from a subsidiary and inflating procurement costs [2][3]. - There were significant omissions in the annual reports regarding related party transactions, particularly concerning the company's control over certain entities [2][3]. Group 3: Investor Compensation - Affected investors who purchased shares between April 23, 2018, and January 8, 2025, and sold or still hold shares after January 9, 2025, are eligible to join the compensation claims [3]. - Investors are advised to prepare relevant transaction documents for the legal team to assess eligibility for claims [3].